130 related articles for article (PubMed ID: 11095579)
1. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber.
Hein DW; McQueen CA; Grant DM; Goodfellow GH; Kadlubar FF; Weber WW
Drug Metab Dispos; 2000 Dec; 28(12):1425-32. PubMed ID: 11095579
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of the human arylamine N-acetyltransferases.
Grant DM; Goodfellow GH; Sugamori K; Durette K
Pharmacology; 2000 Sep; 61(3):204-11. PubMed ID: 10971207
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
4. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
5. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
6. The role of arylamine N-acetyltransferases in chronic degenerative diseases: Their possible function in the immune system.
Hernández-González O; Herrera-Vargas DJ; Martínez-Leija ME; Zavala-Reyes D; Portales-Pérez DP
Biochim Biophys Acta Mol Cell Res; 2022 Sep; 1869(9):119297. PubMed ID: 35588943
[TBL] [Abstract][Full Text] [Related]
7. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
8. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
9. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
10. Arylamine N-acetyltransferases.
Sim E; Westwood I; Fullam E
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
[TBL] [Abstract][Full Text] [Related]
11. Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism.
Stepp MW; Doll MA; Samuelson DJ; Sanders MA; States JC; Hein DW
BMC Cancer; 2017 Mar; 17(1):233. PubMed ID: 28359264
[TBL] [Abstract][Full Text] [Related]
12. 1998 International Meeting on the Arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk.
Ilett KF; Kadlubar FF; Minchin RF
Drug Metab Dispos; 1999 Sep; 27(9):957-9. PubMed ID: 10460790
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic NATs and cancer predisposition.
Hirvonen A
IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility.
Varzim G; Monteiro E; Silva R; Pinheiro C; Lopes C
ORL J Otorhinolaryngol Relat Spec; 2002; 64(3):206-12. PubMed ID: 12037388
[TBL] [Abstract][Full Text] [Related]
15. Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2.
Fakis G; Boukouvala S; Buckle V; Payton M; Denning C; Sim E
Cytogenet Cell Genet; 2000; 90(1-2):134-8. PubMed ID: 11060463
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide sequence of rabbit NAT1 encoding monomorphic arylamine N-acetyltransferase.
Blum M; Heim M; Meyer UA
Nucleic Acids Res; 1990 Sep; 18(17):5287. PubMed ID: 2402454
[No Abstract] [Full Text] [Related]
17. Pharmacogenetics of the arylamine N-acetyltransferases.
Butcher NJ; Boukouvala S; Sim E; Minchin RF
Pharmacogenomics J; 2002; 2(1):30-42. PubMed ID: 11990379
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of cytotoxic drugs.
Daly AK; Hall AG
Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035
[TBL] [Abstract][Full Text] [Related]
19. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population.
Sekine A; Saito S; Iida A; Mitsunobu Y; Higuchi S; Harigae S; Nakamura Y
J Hum Genet; 2001; 46(6):314-9. PubMed ID: 11393533
[TBL] [Abstract][Full Text] [Related]
20. Effect of arylamine acetyltransferase Nat3 gene knockout on N-acetylation in the mouse.
Sugamori KS; Brenneman D; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Drug Metab Dispos; 2007 Jul; 35(7):1064-70. PubMed ID: 17403913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
